. 2020 Sep 18;5(38):24296–24310. doi: 10.1021/acsomega.0c02505

Table 2. In Vitro Screening Data of F7 (1) and Its Extract MBT102 Have Been Executed on Various Cancer Cell Lines, Which Determined Its Potent and Selectivity Activity in the MDA-MB-231 Breast Cancer Cell Line and in Normal Breast Cell Line^a.

		lung	prostate	breast	coloncolon		breast	pancreatic	normal breast epithelial	selectivity index
IC₅₀ (μM)
cell line	A549	PC-3	MCF-7	HT-29	SW620	MDA-MB-231	PANC-1	FR-2
F-7 (1)	μM/mL	10.38 ± 0.14	12.97 ± 0.02	30.23 ± 0.54	22.8 ± 0.14	16.6 ± 0.28	6.86±0.09	10.14 ± 0.43	29.33 ± 1.47	4.27 ± 1.55
MBT102	μg/mL	1.67 ± 0.08	3.41 ± 0.07	2.78 ± 0.72	1.06 ± 0.27	4.42 ± 0.1	2.31 ± 0.40	2.96 ± 0.60	1.48 ± 1.07	0.64 ± 2.18
Paclitaxel	μM/mL	0.01 ± 1.21	0.065 ± 2.36	0.01 ± 0.32	0.03 ± 0.68	0.140 ± 2.20	0.01 ± 1.41	0.037 ± 1.09	0.07 ± 2.38	7 ± 0.11

Paclitaxel was used as a positive control.

Table 2. In Vitro Screening Data of F7 (1) and Its Extract MBT102 Have Been Executed on Various Cancer Cell Lines, Which Determined Its Potent and Selectivity Activity in the MDA-MB-231 Breast Cancer Cell Line and in Normal Breast Cell Linea.